NEW YORK (GenomeWeb News) - NIDDK will grant up to $12.5 million over the next five years to fund research consortia that will discover and validate biomarkers for chronic kidney diseases.
NEW YORK (GenomeWeb News) — The National Institutes of Health will grant up to $12.5 million over the next five years to fund collaborative research projects to find and validate biomarkers for chronic kidney disease.
Funded through the National Institute of Diabetes and Digestive and Kidney Diseases, this program will give up to $2.5 million in 2009 to researchers who will start either biomarker discovery sites or combined discovery/validation sites.
Noting the need for new biomarkers to reduce CKD and kidney failure, NIDDK said in a request for applications that the aim of the program is to identify new biomarkers that reflect kidney function, injury, repair, and progression or regression of damage. Finding these new markers will spur new research that will eventually make its way into the clinic, NIDDK said.
Discovery Sites are eligible for funding of between $250,000 and $350,000 to discover new biomarkers in body fluids such as serum, urine, saliva, or tears, or in tissues from well-characterized patients with CKD, using genomic, proteomic, or metabolomic techniques. These sites also could investigate new imaging techniques for discovering early changes in kidney or vascular structure associated with CKD. These sites also will include access to patient samples or well-characterized cohorts, and the expertise in clinical chemistry and biochemical, proteomic, genomic, or metabolomic methodologies.
Validation Sites may seek between $350,000 and $500,000 in funding to validate previously identified biomarkers in well-defined cohorts with progressive CKD, and to validate biomarkers in samples collected in clinically well-defined, adequately sized populations, including subjects from natural history studies, and clinical trials with specific therapeutic interventions.
It is expected that researchers who are awarded funds under this program will establish a consortium of investigators to work collaboratively, identify new candidate biomarkers for CKD, and to rigorously validate cancer biomarkers with the aim of establishing their utility for research purposes and eventually for clinical use.